gavel-and-lawyer
28 March 2013Big Pharma

The likely role of the UPC in pharma patent litigation

For good or ill for industry in Europe, it now seems likely that the new Unified Patent Court (UPC) will open for business in the next few years and will start to transform European patent litigation. Indeed, the European Commission is talking up the prospect of it opening in 2014, although most think it will be 2015 at the earliest, given all the preparations that have to be made to establish the new court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.